LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 382

Search options

  1. Article: Epigenetic modification and characterization of the

    Weber, Remi / Weller, Michael / Reifenberger, Guido / Vasella, Flavio

    Frontiers in oncology

    2024  Volume 14, Page(s) 1342114

    Abstract: The methylation status of the O6-methylguanine DNA methyltransferase (MGMT) promoter region is a critical predictor of response to alkylating agents in glioblastoma. However, current approaches to study the MGMT status focus on analyzing models with non- ... ...

    Abstract The methylation status of the O6-methylguanine DNA methyltransferase (MGMT) promoter region is a critical predictor of response to alkylating agents in glioblastoma. However, current approaches to study the MGMT status focus on analyzing models with non-identical backgrounds. Here, we present an epigenetic editing approach using CRISPRoff to introduce site-specific CpG methylation in the
    Language English
    Publishing date 2024-01-31
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2024.1342114
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Book: Therapeutic ribonucleic acids in brain tumors

    Erdmann, Volker A. / Reifenberger, Guido / Barciszewski, Jan

    2009  

    Author's details Volker A. Erdmann ; Guido Reifenberger ; Jan Barciszewski ed
    Keywords Brain Neoplasms / therapy ; Glioma / therapy ; RNA, Antisense / therapeutic use ; Gene Therapy
    Language English
    Size XVI, 494 S. : Ill., graph. Darst., 24 cm
    Publisher Springer
    Publishing place Dordrecht u.a.
    Publishing country Netherlands
    Document type Book
    Note Formerly CIP Uk. - Includes bibliographical references and index
    HBZ-ID HT017035181
    ISBN 978-3-642-00474-2 ; 3-642-00474-1 ; 9783642004759 ; 364200475X
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  3. Book ; Online ; Thesis: WNT/β-Catenin-mediated resistance to glucose deprivation in glioblastoma stem-like cells

    Yusuf, Suad [Verfasser] / Reifenberger, Guido [Gutachter]

    2023  

    Author's details Suad Yusuf ; Gutachter: Guido Reifenberger
    Keywords Medizin, Gesundheit ; Medicine, Health
    Subject code sg610
    Language English
    Publisher Universitäts- und Landesbibliothek der Heinrich-Heine-Universität Düsseldorf
    Publishing place Düsseldorf
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    More links

    Kategorien

  4. Book ; Online ; Thesis: Proteasom-Inhibitoren als neue Therapieoptionen für ALK-mutierte Neuroblastome

    Jacobs, Johanna Katharina [Verfasser] / Reifenberger, Guido [Gutachter] / Ghosh, Sujal [Gutachter]

    2024  

    Author's details Johanna Katharina Jacobs ; Gutachter: Guido Reifenberger, Sujal Ghosh
    Keywords Medizin, Gesundheit ; Medicine, Health
    Subject code sg610
    Language English
    Publisher Universitäts- und Landesbibliothek der Heinrich-Heine-Universität Düsseldorf
    Publishing place Düsseldorf
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    More links

    Kategorien

  5. Book ; Thesis: Molekulargenetik der Gliome des Menschen

    Reifenberger, Guido

    1995  

    Author's details vorgelegt von Guido Reifenberger
    Language English
    Size Getr. Zählung
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Düsseldorf, Univ., Habil.-Schr., 1995
    Note Aus: 6 verschiedenen Zeitschriften
    HBZ-ID HT007540043
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  6. Book: Immunhistochemie der Tumoren des Nervensystems

    Reifenberger, Guido

    mit 30 Tabellen

    1991  

    Author's details Guido Reifenberger
    Keywords Immunohistochemistry ; Nervous System Neoplasms / diagnosis ; Nervengeschwulst ; Immuncytochemie ; Tumormarker
    Subject Nervensystem ; Nerventumor ; Immunhistochemie ; Immunocytochemie ; Immunzytochemie ; Immunozytochemie
    Language German
    Size XX, 222 S. : Ill., graph. Darst.
    Publisher Springer
    Publishing place Berlin u.a.
    Document type Book
    HBZ-ID HT003722181
    ISBN 3-540-53066-5 ; 0-387-53066-5 ; 978-3-540-53066-4 ; 978-0-387-53066-6
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  7. Article ; Online: Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?

    Weller, Michael / Reifenberger, Guido

    Current opinion in neurology

    2020  Volume 33, Issue 6, Page(s) 701–706

    Abstract: Purpose of review: The World Health Organization (WHO) classification of central nervous system (CNS) tumors was revised in 2016 to include molecular biomarkers that are important for tumor classification and clinical decision making. Thereafter, the ... ...

    Abstract Purpose of review: The World Health Organization (WHO) classification of central nervous system (CNS) tumors was revised in 2016 to include molecular biomarkers that are important for tumor classification and clinical decision making. Thereafter, the cIMPACT-NOW initiative further refined CNS tumor classification through a series of recommendations likely to shape the upcoming WHO classification 2021.
    Recent findings: Mutations in the isocitrate dehydrogenase (IDH) 1 or 2 genes continue to play a major role in glioma classification. Among IDH-mutant gliomas, loss of ATRX expression identifies IDH-mutant astrocytomas without necessity for 1p/19q codeletion testing. The nomenclature for IDH-mutant glioblastoma has been changed to astrocytoma, IDH-mutant, WHO grade 4, with CDKN2A homozygous deletion representing a novel molecular marker for these tumors. IDH-wildtype astrocytomas that lack microvascular proliferation or necrosis but exhibit telomerase reverse transcriptase promoter mutation, epidermal growth factor receptor amplification, and/or a +7/-10 genotype are now classified as IDH-wildtype glioblastoma. H3.3 G34-mutant diffuse hemispheric gliomas have been proposed as a new entity separate from IDH-wildtype glioblastoma.
    Summary: These changes increase diagnostic accuracy and refine clinical care by changing treatment recommendations, for example for patients with IDH-wildtype astrocytomas showing molecular features of glioblastoma. They also have major implications for clinical trial design.
    MeSH term(s) Brain Neoplasms/classification ; Brain Neoplasms/genetics ; Brain Neoplasms/pathology ; Glioma/classification ; Glioma/genetics ; Glioma/pathology ; Homozygote ; Humans ; Isocitrate Dehydrogenase/genetics ; Mutation ; Promoter Regions, Genetic ; Sequence Deletion ; Telomerase/genetics ; World Health Organization
    Chemical Substances Isocitrate Dehydrogenase (EC 1.1.1.41) ; Telomerase (EC 2.7.7.49)
    Language English
    Publishing date 2020-11-08
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1182686-1
    ISSN 1473-6551 ; 1350-7540
    ISSN (online) 1473-6551
    ISSN 1350-7540
    DOI 10.1097/WCO.0000000000000871
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Book ; Online ; Thesis: Development of a circular RNA detection pipeline and its application in medulloblastoma

    Rickert, Daniel [Verfasser] / Klau, Gunnar [Gutachter] / Reifenberger, Guido [Gutachter]

    2023  

    Author's details Daniel Rickert ; Gutachter: Gunnar Klau, Guido Reifenberger
    Keywords Biowissenschaften, Biologie ; Life Science, Biology
    Subject code sg570
    Language English
    Publisher Universitäts- und Landesbibliothek der Heinrich-Heine-Universität Düsseldorf
    Publishing place Düsseldorf
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    More links

    Kategorien

  9. Article ; Online: Droplet digital PCR-based analyses for robust, rapid, and sensitive molecular diagnostics of gliomas.

    Wolter, Marietta / Felsberg, Jörg / Malzkorn, Bastian / Kaulich, Kerstin / Reifenberger, Guido

    Acta neuropathologica communications

    2022  Volume 10, Issue 1, Page(s) 42

    Abstract: Classification of gliomas involves the combination of histological features with molecular biomarkers to establish an integrated histomolecular diagnosis. Here, we report on the application and validation of a set of molecular assays for glioma ... ...

    Abstract Classification of gliomas involves the combination of histological features with molecular biomarkers to establish an integrated histomolecular diagnosis. Here, we report on the application and validation of a set of molecular assays for glioma diagnostics based on digital PCR technology using the QX200™ Droplet Digital™ PCR (ddPCR) system. The investigated ddPCR-based assays enable the detection of diagnostically relevant glioma-associated mutations in the IDH1, IDH2, H3-3A, BRAF, and PRKCA genes, as well as in the TERT promoter. In addition, ddPCR-based assays assessing diagnostically relevant copy number alterations were studied, including 1p/19q codeletion, gain of chromosome 7 and loss of chromosome 10 (+ 7/-10), EGFR amplification, duplication of the BRAF locus, and CDKN2A homozygous deletion. Results obtained by ddPCR were validated by other methods, including immunohistochemistry, Sanger sequencing, pyrosequencing, microsatellite analyses for loss of heterozygosity, as well as real-time PCR- or microarray-based copy number assays. Particular strengths of the ddPCR approach are (1) its high analytical sensitivity allowing for reliable detection of mutations even with low mutant allele frequencies, (2) its quantitative determination of mutant allele frequencies and copy number changes, and (3) its rapid generation of results within a single day. Thus, in line with other recent studies our findings support ddPCR analysis as a valuable approach for molecular glioma diagnostics in a fast, quantitative and highly sensitive manner.
    MeSH term(s) Brain Neoplasms/diagnosis ; Brain Neoplasms/genetics ; Brain Neoplasms/pathology ; Glioma/diagnosis ; Glioma/genetics ; Glioma/pathology ; Homozygote ; Humans ; Isocitrate Dehydrogenase/genetics ; Pathology, Molecular ; Real-Time Polymerase Chain Reaction ; Sequence Deletion
    Chemical Substances Isocitrate Dehydrogenase (EC 1.1.1.41)
    Language English
    Publishing date 2022-03-31
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2715589-4
    ISSN 2051-5960 ; 2051-5960
    ISSN (online) 2051-5960
    ISSN 2051-5960
    DOI 10.1186/s40478-022-01335-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Glioma.

    Weller, Michael / Wen, Patrick Y / Chang, Susan M / Dirven, Linda / Lim, Michael / Monje, Michelle / Reifenberger, Guido

    Nature reviews. Disease primers

    2024  Volume 10, Issue 1, Page(s) 33

    Abstract: Gliomas are primary brain tumours that are thought to develop from neural stem or progenitor cells that carry tumour-initiating genetic alterations. Based on microscopic appearance and molecular characteristics, they are classified according to the WHO ... ...

    Abstract Gliomas are primary brain tumours that are thought to develop from neural stem or progenitor cells that carry tumour-initiating genetic alterations. Based on microscopic appearance and molecular characteristics, they are classified according to the WHO classification of central nervous system (CNS) tumours and graded into CNS WHO grades 1-4 from a low to high grade of malignancy. Diffusely infiltrating gliomas in adults comprise three tumour types with distinct natural course of disease, response to treatment and outcome: isocitrate dehydrogenase (IDH)-mutant and 1p/19q-codeleted oligodendrogliomas with the best prognosis; IDH-mutant astrocytomas with intermediate outcome; and IDH-wild-type glioblastomas with poor prognosis. Pilocytic astrocytoma is the most common glioma in children and is characterized by circumscribed growth, frequent BRAF alterations and favourable prognosis. Diffuse gliomas in children are divided into clinically indolent low-grade tumours and high-grade tumours with aggressive behaviour, with histone 3 K27-altered diffuse midline glioma being the leading cause of glioma-related death in children. Ependymal tumours are subdivided into biologically and prognostically distinct types on the basis of histology, molecular biomarkers and location. Although surgery, radiotherapy and alkylating agent chemotherapy are the mainstay of glioma treatment, individually tailored strategies based on tumour-intrinsic dominant signalling pathways have improved outcome in subsets of patients.
    MeSH term(s) Humans ; Glioma/genetics ; Glioma/physiopathology ; Glioma/therapy ; Brain Neoplasms/genetics ; Brain Neoplasms/therapy ; Brain Neoplasms/diagnosis ; Brain Neoplasms/physiopathology ; Prognosis ; Child ; Isocitrate Dehydrogenase/genetics ; Mutation
    Chemical Substances Isocitrate Dehydrogenase (EC 1.1.1.41)
    Language English
    Publishing date 2024-05-09
    Publishing country England
    Document type Journal Article ; Review
    ISSN 2056-676X
    ISSN (online) 2056-676X
    DOI 10.1038/s41572-024-00516-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top